Compare Aecom (ACM) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aecom vs Sana Biotechnology Inc — how do they compare? Aecom trades at $61.25 (market cap $8.62B), while Sana Biotechnology Inc trades at $3.79 (market cap $1.13B). The key difference: Aecom is far larger — about 7.6× Sana Biotechnology Inc's market cap, and Aecom pays a 1.77% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| ACM | SANA | |
|---|---|---|
Market Cap | $8.62B | $1.13B |
Sector | Industrials | Health |
52-Week High | $134.35 | $5.92 |
52-Week Low | $66.86 | $2.68 |
Enterprise Value | $10.81B | $1.05B |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACM's stock declined 16.73% to $61.04 amid a Q2 2026 earnings miss, reporting a loss of $0.50 per share versus expectations of $1.46. Despite the recent setback, the company maintains strong analyst support with a 64% buy rating and $88.25 consensus price target. Technical indicators show bearish momentum with the stock trading near key support levels, while fundamentals reveal mixed performance with positive revenue growth but negative ROE and ROA metrics.
The outlook remains cautiously optimistic given the significant analyst upside potential, though investors face near-term volatility from project execution challenges and ongoing securities investigation. Long-term infrastructure demand provides growth tailwinds, but recent earnings volatility and negative profitability ratios warrant careful monitoring of operational improvements.
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aecom
Aecom is one of the largest global providers of design, engineering, construction, and management services. The firm serves a broad spectrum of end markets including infrastructure, water, transportation, and energy. Based in Los Angeles, Aecom has a presence in over 150 countries and employs 51,000. The company generated $13.3 billion in sales and $701 million in adjusted operating income in fiscal 2021.
Read more on ACM →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
